mRNA 치료제 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of mRNA therapeutics Market

The global mRNA therapeutics market was valued at USD 6.01 billion in 2025. The market is projected to grow to USD 6.85 billion in 2026 and further expand to USD 26.06 billion by 2034, exhibiting a strong CAGR of 18.18% during the forecast period (2026-2034).

North America dominated the global market in 2025, accounting for 31.47% market share, driven by robust R&D investments, favorable regulatory support, and early commercialization of mRNA-based COVID-19 vaccines.

The market has undergone rapid transformation following the success of mRNA vaccines during the COVID-19 pandemic. Leading companies such as Moderna Inc., BioNTech, Pfizer Inc., and GSK plc. are actively expanding their pipelines beyond infectious diseases into oncology and rare genetic disorders.

Additionally, the first mRNA drug (non-vaccine therapeutic) is expected to launch in 2027. The mRNA drugs/medications segment alone is projected to reach USD 2 billion by 2032, growing at an exceptional CAGR of 118.7% between 2027 and 2032.

Market Dynamics

Market Drivers

Advantages of mRNA Therapeutics

mRNA-based therapeutics offer several advantages over conventional vaccines and treatments. These include:

• High efficacy in preventing severe illness
• Faster development timelines
• Adaptability to emerging virus strains
• Favorable safety profile
• Lower risk of genomic integration

The rapid response capability demonstrated during the COVID-19 pandemic significantly strengthened confidence in mRNA technology. Growing applications in infectious diseases, oncology, and rare disorders continue to drive market expansion.

Market Restraints

Storage and Stability Challenges

Despite strong demand, mRNA therapeutics require ultra-cold storage conditions, creating logistical challenges. Many low-resource countries lack adequate cold chain infrastructure, limiting widespread adoption.

High Manufacturing Costs

The large-scale production of mRNA products involves complex purification processes and advanced lipid nanoparticle (LNP) delivery systems. These factors significantly increase production costs and limit scalability.

Market Opportunities

Advancements in Drug Delivery Technologies

Ongoing innovations in delivery systems are improving mRNA stability and therapeutic effectiveness. Technologies such as:

• Lipid nanoparticles (LNPs)
• Polymeric nanoparticles
• Cationic nanoparticles

are enhancing intracellular delivery efficiency. These advancements are expected to support commercialization of next-generation mRNA therapies, especially in oncology and rare diseases.

Market Challenges

• Stringent regulatory frameworks across regions
• Evolving approval pathways
• Public perception and vaccine hesitancy
• Infrastructure limitations in developing economies

Addressing these challenges will be essential for sustained long-term growth.

Market Trends

Growing Adoption Beyond Vaccines

While vaccines dominate the market, mRNA technology is increasingly being used for personalized cancer therapies and rare genetic conditions. Nearly 40% of mRNA clinical trials are currently in Phase I, reflecting a rapidly expanding pipeline.

Pharmaceutical companies are heavily investing in oncology-focused mRNA therapeutics, highlighting the technology's potential to revolutionize precision medicine.

Segmentation Analysis

By Type

The market is segmented into:

1. Prophylactic (Vaccines)

2. Drugs/Medications

The prophylactic segment dominated the market in 2024 and is expected to maintain leadership through 2026. In fact, the segment is projected to account for 100% of the market share in 2026, as approved mRNA products currently exist only in the vaccine category (COVID-19 and RSV vaccines).

However, the drugs/medications segment is projected to grow at the fastest rate post-2027, driven by oncology and rare disease pipelines.

By Application

• Infectious Diseases (Dominant in 2024 and expected to contribute 100% share in 2026)
• Oncology (Fastest growing)
• Others

As of January 2025, regulatory approvals exist only for infectious disease applications, reinforcing this segment's dominance.

By Distribution Channel

• Hospital Pharmacies (Largest share in 2024)
• Drug Stores & Retail Pharmacies
• Others

Hospital pharmacies accounted for the highest share due to professional administration requirements. The hospital & retail pharmacies segment is projected to hold 63.62% market share in 2026.

Regional Outlook

North America

North America generated USD 1.89 billion in 2025 and led the global market. The U.S. remains the dominant contributor and is estimated to reach USD 2.16 billion by 2026, supported by strong federal funding and FDA approvals.

Europe

Europe is projected to witness significant growth. Germany is expected to reach USD 0.37 billion by 2026, while the U.K. market is forecast at USD 0.15 billion in 2026.

Asia Pacific

Asia Pacific is anticipated to grow at the fastest rate. By 2026:

• Japan: USD 0.63 billion
• China: USD 0.58 billion
• India: USD 0.27 billion

Increasing R&D investments are fueling regional expansion.

Rest of the World

Latin America and the Middle East & Africa held smaller shares in 2024 but are expected to grow steadily with improving healthcare infrastructure.

Competitive Landscape

The market is highly competitive with key players including:

• Moderna Inc.
• BioNTech
• Pfizer Inc.
• CureVac SE
• GSK plc.
• Sanofi
• Omega Therapeutics
• Strand Therapeutics

These companies focus heavily on R&D, pipeline expansion, and strategic partnerships to strengthen their market presence.

Conclusion

The global mRNA therapeutics market is set for remarkable expansion, increasing from USD 6.01 billion in 2025 to USD 6.85 billion in 2026, and reaching USD 26.06 billion by 2034, growing at a CAGR of 18.18%. North America remains the leading region, supported by strong regulatory backing and innovation ecosystems. While vaccines currently dominate the market, the rapid emergence of mRNA-based drugs for oncology and rare diseases signals the next major growth phase. Overcoming storage, cost, and regulatory challenges will be critical to sustaining this strong upward trajectory through 2034.

Segmentation

By Type

• Prophylactic (Vaccines)
  • COVID-19 Vaccines
  • Non-COVID-19 Vaccines
• Drugs/Medications

By Application

• Oncology
• Infectious Diseases
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Others

By Region

• North America (By Type, Application, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Application, Distribution Channel, and Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific (By Type, Application, Distribution Channel, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of the Asia Pacific
• Rest of the World (By Type, Application, Distribution Channel)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview: Advancements in mRNA Technology
• 4.2. Future Growth Prospects for mRNA Therapeutics
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
• 4.5. Impact of Tariff on the Market

5. Global mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Prophylactic (Vaccines)
    • 5.1.1.1. COVID-19 Vaccines
    • 5.1.1.2. Non-COVID-19 Vaccines
  • 5.1.2. Drugs/Medications
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Oncology
  • 5.2.2. Infectious Diseases
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Drug Stores & Retail Pharmacies
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Prophylactic (Vaccines)
    • 6.1.1.1. COVID-19 Vaccines
    • 6.1.1.2. Non-COVID-19 Vaccines
  • 6.1.2. Drugs/Medications
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Oncology
  • 6.2.2. Infectious Diseases
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Drug Stores & Retail Pharmacies
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Prophylactic (Vaccines)
    • 7.1.1.1. COVID-19 Vaccines
    • 7.1.1.2. Non-COVID-19 Vaccines
  • 7.1.2. Drugs/Medications
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Oncology
  • 7.2.2. Infectious Diseases
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Drug Stores & Retail Pharmacies
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Rest of Europe

8. Asia Pacific mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Prophylactic (Vaccines)
    • 8.1.1.1. COVID-19 Vaccines
    • 8.1.1.2. Non-COVID-19 Vaccines
  • 8.1.2. Drugs/Medications
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Oncology
  • 8.2.2. Infectious Diseases
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Drug Stores & Retail Pharmacies
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Prophylactic (Vaccines)
    • 9.1.1.1. COVID-19 Vaccines
    • 9.1.1.2. Non-COVID-19 Vaccines
  • 9.1.2. Drugs/Medications
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Oncology
  • 9.2.2. Infectious Diseases
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Drug Stores & Retail Pharmacies
  • 9.3.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Moderna Inc.
    • 10.2.1.1. Overview
    • 10.2.1.2. Products & services
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. BioNTech
    • 10.2.2.1. Overview
    • 10.2.2.2. Products & services
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Pfizer Inc.
    • 10.2.3.1. Overview
    • 10.2.3.2. Products & services
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. CureVac SE
    • 10.2.4.1. Overview
    • 10.2.4.2. Products & services
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. GSK plc
    • 10.2.5.1. Overview
    • 10.2.5.2. Products & services
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Sanofi
    • 10.2.6.1. Overview
    • 10.2.6.2. Products & services
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Omega Therapeutics
    • 10.2.7.1. Overview
    • 10.2.7.2. Products & services
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Strand Therapeutics
    • 10.2.8.1. Overview
    • 10.2.8.2. Products & services
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. Immunomic Therapeutics
    • 10.2.9.1. Overview
    • 10.2.9.2. Products & services
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)